JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
SARS-CoV-2 has already infected over 63 million people worldwide. Janus kinase-inhibitors and Type I interferons have emerged as potential antiviral candidates. A search of MEDLINE and MedRxiv was conducted by three investigators from inception until July 30th, 2020. Data with clearly indicated risk estimates were included. Janus kinase-inhibitor treatment is significantly associated with positive clinical outcomes in terms of mortality, ICU admission, and discharge. While these data show promis

Related Post